BioSyent Signs Exclusive Agreement for New Women’s Health Product

BioSyent Inc is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive License and Supply Agreement with a European partner for a new product in the women’s health market for Canada. The product has been approved for sale in Canada, the U.S.A., Europe and in several other markets around the world. BioSyent intends to launch the product to the Canadian market in Q2 2021.

René Goehrum, President and CEO of BioSyent Says: We are pleased to add this new gynecology product to our growing portfolio of women’s health products, including Tibella®, FeraMAX®, and RepaGyn®, We continue to deliver on our goal to bring products to Canada that are unique, differentiated and treat unmet medical needs. This new product is an excellent fit with the healthcare practitioners and patients we currently serve with our Women’s Health franchise and also adds a new group of customers managing infertility issues. As the new product is already approved, we can significantly shorten the time to launch.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital, and international business units.

For further information please contact:

Mr. René C. Goehrum

President and CEO

BioSyent Inc.

E-Mail: investors@biosyent.com

Phone: 905-206-0013

Source: BioSyent

Related Posts

Subscribe Our Newsletter